<DOC>
	<DOCNO>NCT02611024</DOCNO>
	<brief_summary>Prospective , open-label , dose-ranging , uncontrolled phase I study PM01183 combination irinotecan determine maximum tolerate dose ( MTD ) recommend dose ( RD ) PM01183 combination irinotecan patient select advanced solid tumor .</brief_summary>
	<brief_title>Pharmacokinetic Study PM01183 Combination With Irinotecan Patients With Selected Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Voluntarily sign date write informed consent prior specificstudy procedure . Age 18 70 year ( inclusive ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 . Life expectancy ≥ 3 month . No two prior line cytotoxiccontaining chemotherapy regimen advance disease . There limit prior target therapy , hormonal therapy immunotherapy ( nivolumab ) . Histologically cytologically confirm diagnosis advanced disease follow tumor type : 1 . Glioblastoma . 2 . Softtissue sarcoma [ exclude gastrointestinal stromal tumor ( GIST ) ] . 3 . Endometrial carcinoma . 4 . Epithelial ovarian carcinoma ( include primary peritoneal disease and/or fallopian tube carcinoma and/or endometrial adenocarcinoma ) regardless platinum sensitivity . 5 . Mesothelioma . 6 . Gastroenteropancreatic neuroendocrine tumor ( GEPNET ) . 7 . Small cell lung cancer ( SCLC ) . 8 . Pancreatic adenocarcinoma . 9 . Gastric carcinoma . 10 . Colorectal carcinoma ( CRC ) . Expansion phase : Tumorspecific cohort ( ) RD : 1 . Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) v.1.1 . 2 . Documented disease progression per RECIST v.1.1 immediately last therapy accord aforementioned criterion . At least three week since last anticancer therapy , include investigational drug radiotherapy , least six week since nitrosoureas mitomycin C ( systemic ) . Adequate bone marrow , renal , hepatic , metabolic function ( assessed ≤ 7 day inclusion study ) : 1 . Platelet count ≥ 100 × 109/L , hemoglobin ≥ 9.0 g/dL absolute neutrophil count ( ANC ) ≥ 2.0 × 109 /L . 2 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤3.0 × upper limit normal ( ULN ) , even presence liver metastasis . 3 . Alkaline phosphatase ( ALP ) ≤ 2.5 × ULN ( ≤ 5 × ULN diseaserelated/in case liver metastasis ) . 4 . Total bilirubin ≤ 1.5 × ULN direct bilirubin ≤ ULN . 5. International Normalized Ratio ( INR ) &lt; 1.5 ( except patient oral anticoagulation therapy ) . 6 . Calculated creatinine clearance ( CrCL ) ≥ 30 mL/minute ( use CockcroftGault formula ) . 7 . Creatine phosphokinase ( CPK ) ≤ 2.5 × ULN . 8 . Albumin ≥ 3.0 g/dL . Recovery grade ≤ 1 baseline adverse event ( AE ) derive previous treatment ( exclude alopecia and/or cutaneous toxicity and/or peripheral neuropathy and/or fatigue grade ≤ 2 ) . Concomitant diseases/conditions : 1 . History presence unstable angina , myocardial infarction , congestive heart failure , clinically significant valvular heart disease within previous year . 2 . Symptomatic arrhythmia uncontrolled arrhythmia require ongoing treatment . 3 . Ongoing chronic alcohol consumption cirrhosis ChildPugh score B C. Known Gilbert disease . 4 . Active uncontrolled infection . 5 . Known human immunodeficiency virus ( HIV ) know hepatitis C virus ( HCV ) infection active hepatitis B . 6 . Myopathy clinical situation cause significant persistent elevation CPK ( &gt; 2.5 × ULN two different determination perform one week apart ) . 7 . Any past present chronic inflammatory colon and/or liver disease , past intestinal obstruction , pseudo subocclusion paralysis . 8 . Evident symptomatic pulmonary fibrosis interstitial pneumonitis , pleural cardiac effusion rapidly increase and/or necessitate prompt local treatment within seven day . 9 . Limitation patient 's ability comply treatment followup protocol . 10 . Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . Prior treatment PM01183 , trabectedin ( Yondelis® ) topoisomerase I inhibitor ( irinotecan , topotecan , etc. ) . Prior bone marrow stem cell transplantation , radiation therapy 35 % bone marrow . Known brain metastasis leptomeningeal disease involvement . Glioblastoma lesion ( primary locally advance ) eligible . Women pregnant breast feed fertile patient ( men woman ) use effective method contraception . All patient ( men woman ) must agree use effective method contraception ( applicable ) three month treatment discontinuation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>lurbinectedin</keyword>
	<keyword>PM01183</keyword>
	<keyword>tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>Pharma Mar</keyword>
</DOC>